October 22nd, 2010
Dabigatran Resource Round-Up
Our coverage of the FDA’s approval of dabigatran for the prevention of stroke and blood clots in patients with AF has triggered a flurry of comments from CardioExchange members, including questions about when dabigatran will be available, how much it will cost, who should — and shouldn’t — receive it, and what dosages should be prescribed. Check out our dabigatran round-up below and tell us what you think: All future dabigatran comments will reside here. Oh, and by the way, how do you pronounce dabigatran?
- Dabigatran vs Warfarin: War or Peace?
- FDA Approves Dabigatran for Stroke Prevention in Atrial Fibrillation
- Dabigatran Is Approved
- Finally: Dabigatran – A New Oral Anticoagulant Is Approved by the FDA
- Let’s Call the Whole Thing Off!
- What Do I Plan to Do with Dabigatran?
- Warfarin or Dabigatran? The Thick and Thin of Deciding on an Anticoagulant
- Dabigatran to Cost $237 per Month at the Drugstore
- Is Dabigatran More Cost-Effective Than Warfarin in AF?
- RE-LY Substudy Finds Dabigatran Effective in Secondary Stroke Prevention
- A Look Back at 2010
- AF Guidelines Updated to Incorporate Dabigatran
- Dabigatran for Patients with AFib: Putting the Updated Recs into Practice
- Dabigatran Dialogue: Two Experts Answer Our Questions and Yours